Compare ITRN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRN | ANNX |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 873.3M |
| IPO Year | 2005 | 2020 |
| Metric | ITRN | ANNX |
|---|---|---|
| Price | $52.16 | $4.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $74.50 | $15.43 |
| AVG Volume (30 Days) | 77.7K | ★ 3.1M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.43 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.00 | $2.54 |
| 52 Week High | $68.30 | $7.18 |
| Indicator | ITRN | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 42.55 |
| Support Level | $50.17 | $3.71 |
| Resistance Level | $53.04 | $4.37 |
| Average True Range (ATR) | 1.00 | 0.23 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 73.08 | 54.67 |
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.